The National Cancer Institute’s Common Terminology Criteria for Adverse Events (NCI-CTCAE) reporting system is widely used by clinicians to measure patient symptoms in clinical trials. The European Organization for Research and Treatment of Cancer's Quality of Life core questionnaire (EORTC QLQ-C30) enables cancer patients to rate their symptoms related to their quality of life. We examined the extent to which patient and clinician symptom scoring and their agreement could contribute to the estimation of overall survival among cancer patients
Symptomatic adverse event (AE) monitoring is essential in cancer clinical trials to assess patient s...
There is growing interest to enhance symptom monitoring during routine cancer care using patient-rep...
The National Cancer Institute’s Symptom Management and Health-Related Quality of Life Steering Commi...
The National Cancer Institute’s Common Terminology Criteria for Adverse Events (NCI-CTCAE) reporting...
Background The National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE...
Symptomatic adverse events (AEs) are monitored by clinicians as part of all US-based clinical trials...
Symptomatic adverse events (AEs) are monitored by clinicians as part of all US-based clinical trials...
Background: Monitoring adverse events during chemotherapy by clinicians is a standard practice but c...
Background: The National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminol...
Importance: It has been reported that oncologists tend to under-report subjective symptoms during ca...
The National Cancer Institute (NCI) is developing a patient-reported version of its Common Terminolo...
Symptoms are common among patients receiving treatment for advanced cancers, yet are undetected by c...
The National Cancer Institute (NCI) is developing a patient-reported version of its Common Terminolo...
The National Cancer Institute’s Symptom Management and Health-Related Quality of Life Steering Commi...
Symptomatic adverse event (AE) monitoring is essential in cancer clinical trials to assess patient s...
Symptomatic adverse event (AE) monitoring is essential in cancer clinical trials to assess patient s...
There is growing interest to enhance symptom monitoring during routine cancer care using patient-rep...
The National Cancer Institute’s Symptom Management and Health-Related Quality of Life Steering Commi...
The National Cancer Institute’s Common Terminology Criteria for Adverse Events (NCI-CTCAE) reporting...
Background The National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE...
Symptomatic adverse events (AEs) are monitored by clinicians as part of all US-based clinical trials...
Symptomatic adverse events (AEs) are monitored by clinicians as part of all US-based clinical trials...
Background: Monitoring adverse events during chemotherapy by clinicians is a standard practice but c...
Background: The National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminol...
Importance: It has been reported that oncologists tend to under-report subjective symptoms during ca...
The National Cancer Institute (NCI) is developing a patient-reported version of its Common Terminolo...
Symptoms are common among patients receiving treatment for advanced cancers, yet are undetected by c...
The National Cancer Institute (NCI) is developing a patient-reported version of its Common Terminolo...
The National Cancer Institute’s Symptom Management and Health-Related Quality of Life Steering Commi...
Symptomatic adverse event (AE) monitoring is essential in cancer clinical trials to assess patient s...
Symptomatic adverse event (AE) monitoring is essential in cancer clinical trials to assess patient s...
There is growing interest to enhance symptom monitoring during routine cancer care using patient-rep...
The National Cancer Institute’s Symptom Management and Health-Related Quality of Life Steering Commi...